MTOR and pulmonary fibrosis: The bleomycin-mediated pulmonary fibrosis model was adopted for analyzing the therapeutic impacts of nintedanib and evaluating whether or not its inhibitory effects on pulmonary fibrosis are through suppressing PI3K/Akt/mTOR pathway.